These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 21504761

  • 1. Thyromimetics: a journey from bench to bed-side.
    Tancevski I, Rudling M, Eller P.
    Pharmacol Ther; 2011 Jul; 131(1):33-9. PubMed ID: 21504761
    [Abstract] [Full Text] [Related]

  • 2. Lipid lowering with thyroid hormone and thyromimetics.
    Angelin B, Rudling M.
    Curr Opin Lipidol; 2010 Dec; 21(6):499-506. PubMed ID: 20935564
    [Abstract] [Full Text] [Related]

  • 3. Selective thyromimetics using receptor and tissue selectivity approaches: prospects for dyslipidemia.
    Joharapurkar AA, Dhote VV, Jain MR.
    J Med Chem; 2012 Jun 28; 55(12):5649-75. PubMed ID: 22512468
    [No Abstract] [Full Text] [Related]

  • 4. Selective thyromimetics: tissue-selective thyroid hormone analogs.
    Scanlan TS, Yoshihara HA, Nguyen NH, Chiellini G.
    Curr Opin Drug Discov Devel; 2001 Sep 28; 4(5):614-22. PubMed ID: 12825456
    [Abstract] [Full Text] [Related]

  • 5. Thyroid receptor ligands. 1. Agonist ligands selective for the thyroid receptor beta1.
    Ye L, Li YL, Mellström K, Mellin C, Bladh LG, Koehler K, Garg N, Garcia Collazo AM, Litten C, Husman B, Persson K, Ljunggren J, Grover G, Sleph PG, George R, Malm J.
    J Med Chem; 2003 Apr 24; 46(9):1580-8. PubMed ID: 12699376
    [Abstract] [Full Text] [Related]

  • 6. Thyromimetics: a review of recent reports and patents (2004 - 2009).
    Hirano T, Kagechika H.
    Expert Opin Ther Pat; 2010 Feb 24; 20(2):213-28. PubMed ID: 20100003
    [Abstract] [Full Text] [Related]

  • 7. Thyroid receptor ligands. Part 2: Thyromimetics with improved selectivity for the thyroid hormone receptor beta.
    Hangeland JJ, Doweyko AM, Dejneka T, Friends TJ, Devasthale P, Mellström K, Sandberg J, Grynfarb M, Sack JS, Einspahr H, Färnegårdh M, Husman B, Ljunggren J, Koehler K, Sheppard C, Malm J, Ryono DE.
    Bioorg Med Chem Lett; 2004 Jul 05; 14(13):3549-53. PubMed ID: 15177471
    [Abstract] [Full Text] [Related]

  • 8. The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans.
    Berkenstam A, Kristensen J, Mellström K, Carlsson B, Malm J, Rehnmark S, Garg N, Andersson CM, Rudling M, Sjöberg F, Angelin B, Baxter JD.
    Proc Natl Acad Sci U S A; 2008 Jan 15; 105(2):663-7. PubMed ID: 18160532
    [Abstract] [Full Text] [Related]

  • 9. Thyroid hormone analogs for the treatment of dyslipidemia: past, present, and future.
    Delitala AP, Delitala G, Sioni P, Fanciulli G.
    Curr Med Res Opin; 2017 Nov 15; 33(11):1985-1993. PubMed ID: 28498022
    [Abstract] [Full Text] [Related]

  • 10. Thyroid hormone analogues: where do we stand in 2013?
    Meruvu S, Ayers SD, Winnier G, Webb P.
    Thyroid; 2013 Nov 15; 23(11):1333-44. PubMed ID: 23915136
    [Abstract] [Full Text] [Related]

  • 11. Thyroid Hormone Mimetics: the Past, Current Status and Future Challenges.
    Elbers LP, Kastelein JJ, Sjouke B.
    Curr Atheroscler Rep; 2016 Mar 15; 18(3):14. PubMed ID: 26886134
    [Abstract] [Full Text] [Related]

  • 12. Discovery of novel indane derivatives as liver-selective thyroid hormone receptor β (TRβ) agonists for the treatment of dyslipidemia.
    Shiohara H, Nakamura T, Kikuchi N, Ozawa T, Nagano R, Matsuzawa A, Ohnota H, Miyamoto T, Ichikawa K, Hashizume K.
    Bioorg Med Chem; 2012 Jun 01; 20(11):3622-34. PubMed ID: 22542282
    [Abstract] [Full Text] [Related]

  • 13. Selective activation of thyroid hormone signaling pathways by GC-1: a new approach to controlling cholesterol and body weight.
    Baxter JD, Webb P, Grover G, Scanlan TS.
    Trends Endocrinol Metab; 2004 Jun 01; 15(4):154-7. PubMed ID: 15109613
    [Abstract] [Full Text] [Related]

  • 14. Potential Role of Thyroid Receptor β Agonists in the Treatment of Hyperlipidemia.
    Jakobsson T, Vedin LL, Parini P.
    Drugs; 2017 Oct 01; 77(15):1613-1621. PubMed ID: 28865063
    [Abstract] [Full Text] [Related]

  • 15. Thyroid hormone analogs for treatment of hypercholesterolemia and heart failure: past, present and future prospects.
    Morkin E, Ladenson P, Goldman S, Adamson C.
    J Mol Cell Cardiol; 2004 Dec 01; 37(6):1137-46. PubMed ID: 15572044
    [Abstract] [Full Text] [Related]

  • 16. Selective Thyroid Hormone Receptor-Beta (TRβ) Agonists: New Perspectives for the Treatment of Metabolic and Neurodegenerative Disorders.
    Saponaro F, Sestito S, Runfola M, Rapposelli S, Chiellini G.
    Front Med (Lausanne); 2020 Dec 01; 7():331. PubMed ID: 32733906
    [Abstract] [Full Text] [Related]

  • 17. The resurgence of thyromimetics as lipid-modifying agents.
    Tancevski I, Eller P, Patsch JR, Ritsch A.
    Curr Opin Investig Drugs; 2009 Sep 01; 10(9):912-8. PubMed ID: 19705333
    [Abstract] [Full Text] [Related]

  • 18. Thyroid receptor ligands. Part 4: 4'-amido bioisosteric ligands selective for the thyroid hormone receptor beta.
    Li YL, Litten C, Koehler KF, Mellström K, Garg N, Garcia Collazo AM, Färnegård M, Grynfarb M, Husman B, Sandberg J, Malm J.
    Bioorg Med Chem Lett; 2006 Feb 15; 16(4):884-6. PubMed ID: 16303304
    [Abstract] [Full Text] [Related]

  • 19. Recent advances in thyroid research: selective thyroid hormone receptor modulators (STRMs).
    Kraiem Z.
    Pediatr Endocrinol Rev; 2003 Dec 15; 1 Suppl 2():257-60; discussion 260. PubMed ID: 16444167
    [Abstract] [Full Text] [Related]

  • 20. Selective agonists and antagonists to thyroid hormone action.
    Kraiem Z.
    Thyroid; 2005 Apr 15; 15(4):336-9. PubMed ID: 15876155
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.